Current Pharmaceutical Design - Volume 21, Issue 14, 2015

Human serum albumin (HSA) is the most important carrier of exogenous and endogenous molecules in human plasma. Understanding and characterizing the interaction of drugs with HSA has attracted enormous research interests from decades. The nature and magnitude of these bindings have direct consequence on drug delivery, pharmacokinetics, pharmacodynamics, therapeutic efficacy and drug designing. An Read More

Human serum albumin (HSA) is one of the major carrier proteins in the body and constitutes approximately half of the protein found in blood plasma. It plays an important role in lipid metabolism, and its ability to reversibly bind a large variety of pharmaceutical compounds makes it a crucial determinant of drug pharmacokinetics and pharmacodynamics. This review deals with one of the protein’s major binding sites “S Read More

Human serum albumin (HSA) is the major plasma protein with vital functions acting as depot and career for many endogenous (fatty acids, bilirubin, etc.) and exogenous substances (drugs, nutrients, etc.) in the blood. Binding to HSA controls the free, active concentration of the drug and may affect considerably the overall pharmacodynamic and pharmacokinetic profile. Studies on drug – protein binding are important fro Read More

Human serum albumin (HSA) is the most abundant protein in plasma, and plays multiple roles in physiology, including as a carrier protein for endogenous and exogenous compounds. Recent studies provide new evidences to support the enzymatic activities of HSA and new molecular insights for such activities. Here, the structural features and enzymatic characteristics of HSA are reviewed.

Human serum albumin (HSA) represents an important determinant of plasma oncotic pressure and a relevant factor that modulates fluid distribution between the body compartments. Moreover, HSA (i) represents the depot and transporter of several compounds, both endogenous and exogenous, (ii) affects the pharmacokinetics of many drugs, (iii) regulates chemical modifications of some ligands, (iv) shows (pseudo-)e Read More

To date, many potent metal-based anticancer drugs have been developed and many drug delivery systems have been exploited to improve the targeting and decrease the side effects of anticancer drugs. Human serum albumin (HSA) binding contributes significantly to the discovery of new drug candidates because binding of drugs to HSA strongly influences their pharmacokinetic behaviour. Moreover, HSA is widely used in t Read More

Human serum albumin (HSA) regulates the transport and availability of numerous chemical compounds and molecules in the blood vascular system. While previous HSA research has found that HSA interacts with specific varieties of ligands, new research efforts aim to expand HSA’s ability to interact with more different drugs in order to improve the delivery of various pharmacological drugs. This review will cover fatt Read More

Human serum albumin (HSA), a major transport protein component in blood plasma, has been reported recently to play many important roles in pharmacotherapeutics development. Owing to its promising intrinsic binding capability of drug molecules, HSA offers favorable characteristics and can be directly used as its monomeric formula or can be fabricated into protein based nanoparticle platforms to realize the effective del Read More

Albumin has been used as a popular material for carrying imaging probes and/or drugs to provide efficient biomedical imaging and therapy. It is considered as an ideal material for in vivo applications, because albumin is naturally abundant in serum to show non-toxicity and non-immunogenicity. In addition, based on the convenience of chemical modifications, it is widely used for the delivery of diverse molecules i Read More

Fusion proteins have been well-studied and widely applied in biopharmaceutics. Albumin fusion proteins are simple to construct, easy to purify, and stable to formulate. One main application of fusion protein is to extend the plasma half-life of therapeutic proteins and peptides. Albiglutide for diabetes treatment is the first albumin fusion protein drug approved by FDA. Balugrastim and other albumin fusion proteins have been e Read More

Human serum albumin (HSA) is an abundant protein in blood and tissue fluids and has been used as a carrier for drug delivery. HSA can improve the pharmacokinetic profiles of drugs, such as extending the blood half-life of existing drugs and reducing toxic side effects. At the same time, more and more molecular imaging probes conjugated or fused with HSA have been studied to achieve higher specificity and better phar Read More